Well I am going to be sedated and I am going to have to have it done. Now they are fighting over whether or not to do it while I'm on Coumadin. I presented the guidelines from the ASGE and I might just as well have thrown them in the waste can.
3. Elective endoscopic procedure in the patient
taking warfarin who may need bridge therapy.
LMWH may be useful in extending the period of
systemic anticoagulation while the effects of long-acting
warfarin are allowed to dissipate. LMWH may replace the
previous standard of a ‘‘heparin window’’ in high-risk
patients. Considerations in favor of LMWH would be the
enhanced quality of life for the patient (i.e., no therapeutic
monitoring, avoidance of hospitalization, no need for
intravenous access) and the possible economic savings of
outpatient LMWHcompared with a hospital-based ‘‘heparin
window.’’31 LMWH should not be used in pregnant women
with mechanical prosthetic heart valves. In non-pregnant
patients with mechanical valves, short-term use appears to
be safe but prospective controlled data are lacking.
Low-risk procedure. No adjustments in anticoagulation
need be made, irrespective of the underlying
condition.
High-risk procedure. Discontinue warfarin 3 to 5
days before the procedure and concomitantly begin
administering LMWH. Consider using dose ranges as for
the treatment of patients with acute DVT (e.g., enoxaparin
1 mg/kg subcutaneously every 12 hours). Discontinue
LMWH for at least 8 hours before the therapeutic
endoscopy. The decision as to when to restart therapy
should be individualized.
ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures
190 GASTROINTESTINAL ENDOSCOPY Volume 61, No. 2 : 2005
www.mosby.com/gie